Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Wilhelm

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
The Laryngoscope|December 21, 2007
Molecular classification of thyroid nodules by cytologyNitin A Pagedar, Daniel H Chen, Jay K Wasman, et al.
Surgery|May 18, 2024
What constitutes quality in endocrine surgery? Statement from the American Association of Endocrine SurgeonsAarti Mathur, Kepal N Patel, Scott M Wilhelm, et al.
International Journal of Cancer|December 21, 2010
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityScott M Wilhelm, Jacques Dumas, Lila Adnane, et al.
Surgical Endoscopy|November 1, 2021
A comparison of robotic and laparoscopic minimally invasive adrenalectomy for adrenal malignanciesJonathan J Hue, Peter Ahorukomeye, Katherine Bingmer, et al.
Annals of Surgical Oncology|August 11, 2007
Outcomes of pheochromocytoma management in the laparoscopic eraCarmen C Solorzano, John I Lew, Scott M Wilhelm, et al.
Surgery|October 12, 2014
Feasibility of surgeon-performed transcutaneous vocal cord ultrasonography in identifying vocal cord mobility: A multi-institutional experienceDenise Carneiro-Pla, Barbra S Miller, Scott M Wilhelm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
BRAF is a therapeutic target in aggressive thyroid carcinomaGiuliana Salvatore, Valentina De Falco, Paolo Salerno, et al.
International Journal of Cancer|December 19, 2013
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancerRoberta Schmieder, Jens Hoffmann, Michael Becker, et al.
Molecular Cancer Therapeutics|October 31, 2013
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft modelsNingshu Liu, Bruce R Rowley, Cathy O Bull, et al.
JAMA Surgery|August 18, 2016
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary HyperparathyroidismScott M Wilhelm, Tracy S Wang, Daniel T Ruan, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
The Laryngoscope|December 21, 2007
Molecular classification of thyroid nodules by cytologyNitin A Pagedar, Daniel H Chen, Jay K Wasman, et al.
Surgery|May 18, 2024
What constitutes quality in endocrine surgery? Statement from the American Association of Endocrine SurgeonsAarti Mathur, Kepal N Patel, Scott M Wilhelm, et al.
International Journal of Cancer|December 21, 2010
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityScott M Wilhelm, Jacques Dumas, Lila Adnane, et al.
Surgical Endoscopy|November 1, 2021
A comparison of robotic and laparoscopic minimally invasive adrenalectomy for adrenal malignanciesJonathan J Hue, Peter Ahorukomeye, Katherine Bingmer, et al.
Annals of Surgical Oncology|August 11, 2007
Outcomes of pheochromocytoma management in the laparoscopic eraCarmen C Solorzano, John I Lew, Scott M Wilhelm, et al.
Surgery|October 12, 2014
Feasibility of surgeon-performed transcutaneous vocal cord ultrasonography in identifying vocal cord mobility: A multi-institutional experienceDenise Carneiro-Pla, Barbra S Miller, Scott M Wilhelm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
BRAF is a therapeutic target in aggressive thyroid carcinomaGiuliana Salvatore, Valentina De Falco, Paolo Salerno, et al.
International Journal of Cancer|December 19, 2013
Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancerRoberta Schmieder, Jens Hoffmann, Michael Becker, et al.
Molecular Cancer Therapeutics|October 31, 2013
BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft modelsNingshu Liu, Bruce R Rowley, Cathy O Bull, et al.
JAMA Surgery|August 18, 2016
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary HyperparathyroidismScott M Wilhelm, Tracy S Wang, Daniel T Ruan, et al.
Pageof 5